{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H5N1+Antigen",
    "query": {
      "intervention": "H5N1 Antigen"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H5N1+Antigen&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-19T03:08:45.238Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01938742",
      "title": "H7N9 Mix and Match With MF59 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "19 Years to 64 Years"
      },
      "enrollment_count": 700,
      "start_date": "2013-09",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2016-12-12",
      "last_synced_at": "2026-09-19T03:08:45.238Z",
      "location_count": 4,
      "location_summary": "Decatur, Georgia • Iowa City, Iowa • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01938742"
    },
    {
      "nct_id": "NCT05397119",
      "title": "A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza, Pandemic"
      ],
      "interventions": [
        {
          "name": "BW-1014: 25 µg rH5 in 20% NE - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BW-1014: 50 µg rH5 in 20% NE - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BW-1014: 100 µg rH5 in 20% NE - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rH5 (100 µg) control - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline (Placebo) - pipette - IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H5N1 IIV - IM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BlueWillow Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-07-07",
      "completion_date": "2023-10-12",
      "has_results": true,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-19T03:08:45.238Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05397119"
    },
    {
      "nct_id": "NCT06560151",
      "title": "Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "3.75 µg H5N8 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N8 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N8 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.75 µg H5N8 antigen plus half dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N8 antigen plus half dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N8 antigen plus half dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.75 µg H5N8 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N8 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N8 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.75 µg H5N1 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N1 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N1 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.75 µg H5N1 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N1 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N1 antigen plus MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1380,
      "start_date": "2024-08-21",
      "completion_date": "2025-06-11",
      "has_results": true,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-09-19T03:08:45.238Z",
      "location_count": 20,
      "location_summary": "Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06560151"
    },
    {
      "nct_id": "NCT02078674",
      "title": "A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza (Pandemic)"
      ],
      "interventions": [
        {
          "name": "Monovalent Avian Influenza VLP (H7N9)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matrix-M1™ adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 610,
      "start_date": "2014-03",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2016-09-23",
      "last_synced_at": "2026-09-19T03:08:45.238Z",
      "location_count": 5,
      "location_summary": "Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more",
      "locations": [
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Endwell",
          "state": "New York"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02078674"
    },
    {
      "nct_id": "NCT01942265",
      "title": "H7N9 Mix and Match With AS03 and MF59 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "MF59",
          "type": "DRUG"
        },
        {
          "name": "Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "19 Years to 64 Years"
      },
      "enrollment_count": 980,
      "start_date": "2013-09",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-06",
      "last_synced_at": "2026-09-19T03:08:45.238Z",
      "location_count": 5,
      "location_summary": "Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01942265"
    },
    {
      "nct_id": "NCT03345043",
      "title": "Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "VAL-339851",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 156,
      "start_date": "2016-05-11",
      "completion_date": "2018-08-13",
      "has_results": false,
      "last_update_posted_date": "2021-01-11",
      "last_synced_at": "2026-09-19T03:08:45.238Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345043"
    },
    {
      "nct_id": "NCT00912496",
      "title": "Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "MF-59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "A/Anhui/05",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 637,
      "start_date": "2010-06",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2013-05-14",
      "last_synced_at": "2026-09-19T03:08:45.238Z",
      "location_count": 10,
      "location_summary": "Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00912496"
    },
    {
      "nct_id": "NCT01596725",
      "title": "A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza (Pandemic)"
      ],
      "interventions": [
        {
          "name": "Monovalent Avian Influenza VLP (H5N1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Monovalent Avian Influenza VLP (H5N1); Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 333,
      "start_date": "2012-05",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2014-02-06",
      "last_synced_at": "2026-09-19T03:08:45.238Z",
      "location_count": 5,
      "location_summary": "Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01596725"
    },
    {
      "nct_id": "NCT02839330",
      "title": "A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Avian Influenza"
      ],
      "interventions": [
        {
          "name": "aH5N1c",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3196,
      "start_date": "2016-07-11",
      "completion_date": "2017-10-04",
      "has_results": true,
      "last_update_posted_date": "2024-12-06",
      "last_synced_at": "2026-09-19T03:08:45.238Z",
      "location_count": 26,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02839330"
    },
    {
      "nct_id": "NCT01657929",
      "title": "H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza A Subtype H5N1 Infection"
      ],
      "interventions": [
        {
          "name": "H5-VLP + GLA-AF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H5-VLP alone",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H5-VLP + Alhydrogel(R)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed H5N1 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Access to Advanced Health Institute (AAHI)",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 105,
      "start_date": "2012-09",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2014-02-26",
      "last_synced_at": "2026-09-19T03:08:45.238Z",
      "location_count": 3,
      "location_summary": "Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01657929"
    }
  ]
}